Most requests for authorization to bear health claims under Articles 13(5) and 14 related to blood glucose and insulin concentration/regulation presented to the European Food Safety Authority (EFSA) receive a negative opinion. Reasons for such decisions are mainly ascribable to poor substantiation of the claimed effects. In this scenario, a project was carried out aiming at critically analysing the outcome variables (OVs) and methods of measurement (MMs) to be used to substantiate health claims, with the final purpose to improve the quality of applications provided by stakeholders to EFSA. This manuscript provides a position statement of the experts involved in the project, reporting the results of an investigation aimed to collect, collate and critically analyse the information relevant to claimed effects (CEs), OVs and MMs related to blood glucose and insulin levels and homoeostasis compliant with Regulation 1924/2006. The critical analysis of OVs and MMs was performed with the aid of the pertinent scientific literature and was aimed at defining their appropriateness (alone or in combination with others) to support a specific CE. The results can be used to properly select OVs and MMs in a randomized controlled trial, for an effective substantiation of the claims, using the reference method(s) whenever available. Moreover, results can help EFSA in updating the guidance for the scientific requirements of health claims.

Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the area of blood glucose and insulin concentrations / D. Martini, B. Biasini, I. Zavaroni, G. Bedogni, M. Musci, C. Pruneti, G. Passeri, M. Ventura, D. Galli, P. Mirandola, M. Vitale, A. Dei Cas, R.C. Bonadonna, D. Del Rio. - In: ACTA DIABETOLOGICA. - ISSN 0940-5429. - 55:4(2018), pp. 391-404. [10.1007/s00592-017-1095-6]

Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the area of blood glucose and insulin concentrations

D. Martini;G. Bedogni;
2018

Abstract

Most requests for authorization to bear health claims under Articles 13(5) and 14 related to blood glucose and insulin concentration/regulation presented to the European Food Safety Authority (EFSA) receive a negative opinion. Reasons for such decisions are mainly ascribable to poor substantiation of the claimed effects. In this scenario, a project was carried out aiming at critically analysing the outcome variables (OVs) and methods of measurement (MMs) to be used to substantiate health claims, with the final purpose to improve the quality of applications provided by stakeholders to EFSA. This manuscript provides a position statement of the experts involved in the project, reporting the results of an investigation aimed to collect, collate and critically analyse the information relevant to claimed effects (CEs), OVs and MMs related to blood glucose and insulin levels and homoeostasis compliant with Regulation 1924/2006. The critical analysis of OVs and MMs was performed with the aid of the pertinent scientific literature and was aimed at defining their appropriateness (alone or in combination with others) to support a specific CE. The results can be used to properly select OVs and MMs in a randomized controlled trial, for an effective substantiation of the claims, using the reference method(s) whenever available. Moreover, results can help EFSA in updating the guidance for the scientific requirements of health claims.
Blood glucose; Claimed effect; Diabetes; Insulin; Measurement method; Outcome variable; Area Under Curve; Blood Glucose; Diabetes Mellitus, Type 2; Humans; Insulin; Patient Outcome Assessment; Postprandial Period; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome; European Union; Legislation as Topic
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
Martini_bone_Pharmanutrition_preprint.pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 792.15 kB
Formato Adobe PDF
792.15 kB Adobe PDF Visualizza/Apri
Martini_et_al-2018-Acta_Diabetologica (1).pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 897.79 kB
Formato Adobe PDF
897.79 kB Adobe PDF Visualizza/Apri
Martini2018_Article_ClaimedEffectsOutcomeVariables.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 880.99 kB
Formato Adobe PDF
880.99 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/803381
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 2
social impact